Use of L-carnitine and its alkanoyl derivatives for reducing the

Details Use of L-carnitine and its alkanoyl derivatives for reducing the Use of L-carnitine and its alkanoyl derivatives for reducing the

1996-01-03

1999-09-21

Goldberg, Jerome D.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514556, A61K 3800, A61K 31205

Patent

active

059554240

ABSTRACT:
The use of L-carnitine or of an alkanoyl L-carnitine or their pharmacologically acceptable salts is described for producing a medicament for inhibiting nephrotoxicity and vasculotoxicity resulting from the administration of an immunosuppressant drug such as cyclosporin-A, tacrolimus, rapamicine and deoxyspergualine.

REFERENCES:
Wanner et al, Metabolism, "Serum Carnitine Levels and Carnitine Esters of Patients after Kidney Transplantation: Role of Immunosuppression", vol., 37, No. 3, (Mar., 1988) pp. 263-267.

Affiliated with

Also associated with

Rating

Use of L-carnitine and its alkanoyl derivatives for reducing the does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of L-carnitine and its alkanoyl derivatives for reducing the, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of L-carnitine and its alkanoyl derivatives for reducing the will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-80207